Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Alector

DB:0Z2
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0Z2
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. The last earnings update was 13 days ago. More info.


Add to Portfolio Compare Print
  • Alector has significant price volatility in the past 3 months.
0Z2 Share Price and Events
7 Day Returns
-6.3%
DB:0Z2
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-1.1%
DB:0Z2
-13.5%
DE Biotechs
-20.9%
DE Market
0Z2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Alector (0Z2) -6.3% -20% 44.4% -1.1% - -
DE Biotechs -0.7% -7.8% -21.1% -13.5% 12.9% -11.9%
DE Market -0.6% -16.6% -26% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 0Z2 outperformed the Biotechs industry which returned -13.5% over the past year.
  • 0Z2 outperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

0Z2 Value

 Is Alector undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Alector. This is due to cash flow or dividend data being unavailable. The share price is €20.8.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Alector's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Alector's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0Z2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.71
NasdaqGS:ALEC Share Price ** NasdaqGS (2020-04-03) in USD $21.9
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Alector.

DB:0Z2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ALEC Share Price ÷ EPS (both in USD)

= 21.9 ÷ -1.71

-12.83x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alector is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Alector is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Alector's expected growth come at a high price?
Raw Data
DB:0Z2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -12.83x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
13.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.16x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Alector, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Alector's assets?
Raw Data
DB:0Z2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $2.82
NasdaqGS:ALEC Share Price * NasdaqGS (2020-04-03) in USD $21.9
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:0Z2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ALEC Share Price ÷ Book Value per Share (both in USD)

= 21.9 ÷ 2.82

7.77x

* Primary Listing of Alector.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alector is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Alector's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Alector has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

0Z2 Future Performance

 How is Alector expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Alector expected to grow at an attractive rate?
  • Unable to compare Alector's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Alector's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Alector's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:0Z2 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0Z2 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 13.1%
DB:0Z2 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 39.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0Z2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0Z2 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 266 -113 -12 1
2023-12-31 250 -168 -8 1
2022-12-31 50 -215 -189 1
2021-12-31 48 -184 -166 3
2020-12-31 42 -150 -136 3
2020-04-06
DB:0Z2 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 21 -99 -105
2019-09-30 24 -88 -92
2019-06-30 28 -82 -76
2019-03-31 28 -81 -62
2018-12-31 28 127 -52
2018-09-30 22 143 -45
2018-06-30 15 159 -39
2018-03-31 8 171 -35
2017-12-31 4 -18 -32

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Alector is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Alector's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0Z2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Alector Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0Z2 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.13 -0.13 -0.13 1.00
2023-12-31 -0.09 -0.09 -0.09 1.00
2022-12-31 -2.08 -2.08 -2.08 1.00
2021-12-31 -2.03 -1.90 -2.12 3.00
2020-12-31 -1.75 -1.68 -1.78 3.00
2020-04-06
DB:0Z2 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.71
2019-09-30 -1.93
2019-06-30 -2.25
2019-03-31 -3.19
2018-12-31 -4.62
2018-09-30 -3.24
2018-06-30 -3.79
2018-03-31 -3.55
2017-12-31 -3.55

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Alector will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Alector's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Alector has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

0Z2 Past Performance

  How has Alector performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Alector's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Alector does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Alector's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Alector's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Alector's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Alector Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0Z2 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 21.22 -105.39 33.94
2019-09-30 24.36 -92.23 25.42
2019-06-30 28.17 -75.81 20.02
2019-03-31 28.36 -62.37 15.27
2018-12-31 27.68 -52.25 11.93
2018-09-30 21.59 -44.65 9.90
2018-06-30 15.24 -39.37 9.23
2018-03-31 8.39 -34.58 7.82
2017-12-31 3.74 -32.48 6.50
2016-12-31 0.42 -15.11 1.87

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Alector has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Alector has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Alector improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Alector's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Alector has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

0Z2 Health

 How is Alector's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Alector's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Alector is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Alector's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Alector's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.0304785625263E+16x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Alector Company Filings, last reported 3 months ago.

DB:0Z2 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 194.74 0.00 353.07
2019-09-30 218.59 0.00 381.45
2019-06-30 245.72 0.00 410.93
2019-03-31 266.19 0.00 436.60
2018-12-31 113.12 0.00 290.41
2018-09-30 127.39 0.00 308.69
2018-06-30 78.17 0.00 268.10
2018-03-31 25.45 0.00 32.45
2017-12-31 25.45 0.00 32.45
2016-12-31 52.58 0.00 50.84
  • Alector's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Alector's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Alector has sufficient cash runway for more than 3 years based on current free cash flow.
  • Alector has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 55.8% each year.
X
Financial health checks
We assess Alector's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Alector has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

0Z2 Dividends

 What is Alector's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Alector dividends. Estimated to be 0% next year.
If you bought €2,000 of Alector shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Alector's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Alector's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0Z2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 315 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0Z2 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 2.00
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Alector has not reported any payouts.
  • Unable to verify if Alector's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Alector's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Alector has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Alector's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Alector's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Alector afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Alector has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

0Z2 Management

 What is the CEO of Alector's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Arnon Rosenthal
COMPENSATION $6,775,588
AGE 63
TENURE AS CEO 7.3 years
CEO Bio

Dr. Arnon Rosenthal, Ph.D., Co-Founded of Alector, Inc. in 2013 and serves as its Chief Executive Officer and Director since 2013 and served as its President since 2013. He served as Chief Scientific Officer of Alector, Inc. (formerly Alector LLC). Dr. Rosenthal co-founded Annexon Biosciences, Inc. and served as its acting Chief Executive Officer from August 2011 to December 2014 and served as a member of the board of directors, including as Chairman from August 2011 February 2017. He co-founded Rinat Neuroscience Corporation (acquired by Pfizer Inc. in August 2006) in October 2001 and served as President, Chief Scientific Officer and as a member of the board of directors from August 2001 to August 2006. From January 1985 to August 2001, Dr. Rosenthal served in various roles at Genentech, Inc., where he ultimately served as Staff Scientist and was appointed as a permanent member of Genentech’s Research Review Committee where his team discovered the target for the cancer drug Erivedge. Dr. Rosenthal conducted his post-doctoral fellowship at Genentech, Inc. Dr. Rosenthal is a Visiting Professor of the Department of Anatomy at the University of California San Francisco and a Member of the Scientific Advisory Board of Simons Foundation, Autism Research Initiative and the Myelin Repair Foundation. He is a Member of the NIH Advisory Committee on Parkinson's Disease and Neuronal Repair. He is a Leader in the field of neurological disease, publishing over 70 articles on the topic. Dr. Rosenthal holds a Ph.D. in biology from the Hebrew University of Jerusalem.

CEO Compensation
  • Arnon's compensation has increased whilst company is loss making.
  • Arnon's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Alector management team in years:

2.8
Average Tenure
51
Average Age
  • The tenure for the Alector management team is about average.
Management Team

Tillman Gerngross

TITLE
Co-Founder & Chairman
COMPENSATION
$314K
AGE
55
TENURE
7.3 yrs

Arnon Rosenthal

TITLE
Co-Founder
COMPENSATION
$7M
AGE
63
TENURE
7.3 yrs

Robert Paul

TITLE
Chief Medical Officer
COMPENSATION
$2M
AGE
51
TENURE
3.5 yrs

Robert King

TITLE
Chief Development Officer
COMPENSATION
$2M
AGE
56
TENURE
3.3 yrs

Shehnaaz Suliman

TITLE
President & COO
AGE
47
TENURE
0.3 yrs

Calvin Yu

TITLE
Vice President of Finance
AGE
42
TENURE
2.8 yrs

Charles Wolfus

TITLE
Vice President of Technology & Digital Health
TENURE
1.3 yrs

Stephanie Yonker

TITLE
Vice President of Legal
TENURE
2.7 yrs

Clare Hunt

TITLE
Head of People

Sabah Oney

TITLE
Chief Business Officer
AGE
36
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the Alector board of directors in years:

7.3
Average Tenure
63
Average Age
  • The tenure for the Alector board of directors is about average.
Board of Directors

Arnon Rosenthal

TITLE
Co-Founder
COMPENSATION
$7M
AGE
63
TENURE
7.3 yrs

Terry McGuire

TITLE
Independent Director
COMPENSATION
$306K
AGE
63
TENURE
7.3 yrs

Tillman Gerngross

TITLE
Co-Founder & Chairman
COMPENSATION
$314K
AGE
55
TENURE
7.3 yrs

Dave Wehner

TITLE
Independent Director
COMPENSATION
$303K
AGE
50
TENURE
1.5 yrs

Louis Lavigne

TITLE
Lead Independent Director
COMPENSATION
$332K
AGE
70
TENURE
1.5 yrs

Adam Boxer

TITLE
Member of Scientific Advisory Board

Marco Colonna

TITLE
Member of Scientific Advisory Board

Stephen Hauser

TITLE
Member of Scientific Advisory Board

Michael Heneka

TITLE
Member of Scientific Advisory Board

Lewis Lanier

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Alector individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
02. Apr 20 Sell OrbiMed Advisors LLC Company 31. Mar 20 31. Mar 20 -250,000 €22.30 €-5,573,750
25. Mar 20 Sell OrbiMed Advisors LLC Company 23. Mar 20 25. Mar 20 -138,653 €24.04 €-3,161,181
04. Mar 20 Sell OrbiMed Advisors LLC Company 02. Mar 20 02. Mar 20 -1,874,203 €23.32 €-43,710,162
04. Mar 20 Sell OrbiMed Advisors LLC Company 02. Mar 20 02. Mar 20 -16,797 €23.32 €-391,740
03. Feb 20 Buy David Wehner Individual 03. Feb 20 03. Feb 20 20,000 €22.61 €452,150
13. Jan 20 Sell OrbiMed Advisors LLC Company 20. Dec 19 09. Jan 20 -25,603 €17.86 €-453,457
13. Jan 20 Sell OrbiMed Advisors LLC Company 09. Jan 20 09. Jan 20 -379,997 €17.57 €-6,677,098
26. Dec 19 Sell OrbiMed Advisors LLC Company 20. Dec 19 26. Dec 19 -519,385 €17.85 €-9,196,916
19. Dec 19 Sell OrbiMed Advisors LLC Company 17. Dec 19 17. Dec 19 -954,100 €16.61 €-15,842,861
19. Dec 19 Sell OrbiMed Advisors LLC Company 17. Dec 19 17. Dec 19 -45,900 €16.61 €-762,171
09. Aug 19 Sell OrbiMed Advisors LLC Company 07. Aug 19 07. Aug 19 -650,000 €15.94 €-10,360,968
X
Management checks
We assess Alector's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Alector has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

0Z2 News

Simply Wall St News

0Z2 Company Info

Description

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its product includes AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.

Details
Name: Alector, Inc.
0Z2
Exchange: DB
Founded: 2013
$1,603,484,977
78,992,871
Website: http://www.alector.com
Address: Alector, Inc.
131 Oyster Point Boulevard,
Suite 600,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ALEC Common Stock Nasdaq Global Select US USD 07. Feb 2019
DB 0Z2 Common Stock Deutsche Boerse AG DE EUR 07. Feb 2019
Number of employees
Current staff
Staff numbers
121
Alector employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 03:27
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/25
Last earnings filing: 2020/03/24
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.